Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

DICP scientists develop high-efficiency CO2 hydrogenation catalyst

26

Mar 2026

DICP scientists develop high-efficiency CO2 hydrogenation catalyst

Formate is a key chemical building block widely used across industries. Converting carbon dioxide (CO2) into formate via hydrogenation provides a promising approach to transform a greenhouse gas into a high-value chemical. However, while heterogeneous catalysts based on non-precious metals have been explored for this reaction, their practical application has been limited by low intrinsic reactivity.

Analyzing the disparity between youth and adult HPV uptake

26

Mar 2026

Analyzing the disparity between youth and adult HPV uptake

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and can cause various types of cancer. Prophylactic HPV vaccination is highly effective and has been recommended in Switzerland since 2007 for girls and young women aged 11 to 26 – and since 2015 also for boys and young men. Catch-up vaccination is also available for women up to the age of 45.

Study links androgens to aggressive childhood brain tumor growth

25

Mar 2026

Study links androgens to aggressive childhood brain tumor growth

An international team led by researchers at Baylor College of Medicine, Texas Children's Hospital, McGill University and University of Pittsburgh School of Medicine has discovered what drives the growth of a lethal pediatric brain tumor called Posterior Fossa Type A (PFA) ependymoma.

New brain atlas reveals how the human neocortex forms over time

25

Mar 2026

New brain atlas reveals how the human neocortex forms over time

In a bid to better understand, and potentially treat, a host of conditions that affect early cognition, neurodevelopment and the brain later in life, investigators at Johns Hopkins Medicine and colleagues throughout the world have been mapping the molecular construction of the human brain.

Childhood ADHD medication shows protective effect against future psychosis

25

Mar 2026

Childhood ADHD medication shows protective effect against future psychosis

A major new study, led by scientists at University College Dublin and the University of Edinburgh and funded by the St John of God Research Foundation, has found that commonly prescribed attention deficit hyperactivity disorder (ADHD) medication in childhood may lower the long‑term risk of developing serious psychotic disorders, including schizophrenia.

Study links social media addiction to worse student mental health and points to family as a key buffer

25

Mar 2026

Study links social media addiction to worse student mental health and points to family as a key buffer

A study of 627 Saudi university students found that higher social media addiction was associated with more anxiety and depression, while family environment fully mediated those links in the statistical model. The findings suggest that supportive family relationships may help buffer the mental health burden associated with problematic social media use, although the cross-sectional design does not establish causation.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.